Additional file 1: of Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Autor: Foeldvari, Ivan, Tamàs Constantin, Vojinović, Jelena, Horneff, Gerd, Chasnyk, Vyacheslav, Dehoorne, Joke, Panaviene, Violeta, Sušić, Gordana, Stanevicha, Valda, Kobusinska, Katarzyna, Zuber, Zbigniew, Bogna Dobrzyniecka, Nikishina, Irina, Bader-Meunier, Brigitte, Breda, Luciana, Doležalová, Pavla, Job-Deslandre, Chantal, Rumba-Rozenfelde, Ingrida, Wulffraat, Nico, Pedersen, Ronald, Bukowski, Jack, Vlahos, Bonnie, Martini, Alberto, Ruperto, Nicolino
Rok vydání: 2019
DOI: 10.6084/m9.figshare.8179943
Popis: Table S1. Summary of missing data imputation methods for the responder analysis. Table S2. Disease activity and patient-reported outcomes (observed cases). Table S3. Outcomes specific for enthesitis-related arthritis and psoriatic arthritis (observed cases). Table S4. The most frequent TEAEs, excluding infections and injection site reactions (> 5% in any JIA subtype, by System Organ Class). Figure S1. ACR30–100 and JIA inactive disease response rates (OC vs NRI). Additional Tables (A1 to A4) and Figure A1 related to missing data imputation based on patients’ enrolment status, trial period at cut-off date, and reasons for permanent discontinuation. (DOCX 224 kb)
Databáze: OpenAIRE